Summary
January 2007, Vol. 16, No. 1, Pages 1-10 , DOI 10.1517/13543784.16.1.1

Discontinued drugs in 2005: anti-infectives

Nafsika Georgopapadakou
MethylGene, Inc., 7220 Frederick-Banting, Montreal, QC H4S 2A1, Canada.



This perspective is the fifth in a series discussing drugs dropped from development in 2005, of which 11 were being developed for infectious diseases. Of these, eight were antivirals and were dropped in Phase II or III: Medivir's alovudine, Ono Pharmaceuticals' aplaviroc hydrochloride and Excite's immunotherapeutic Xcellerate™ for HIV; Boehringer Ingelheim's ciluprevir, ViroPharma's HCV-086, Isis Pharmaceuticals' antisense oligonucleotide ISIS-14803, Japan Tobacco's JTK-003 and Rigel's R803 for hepatitis C virus. The remaining discontinued anti-infective drugs were an antibacterial vaccine (Vical's anthrax vaccine), an antiseptic (YM Bioscience's Dermofural™) and an antifungal formulation (MacroChem's topical econazole). The drugs are grouped by compound class and reasons for their failure are discussed in this article.

Full Text | PDF (151 KB) | PDF Plus (225 KB)

Forward Links to Citing Articles

Liesbeth Lenaerts, Erik De Clercq, Lieve Naesens. (2008) Clinical features and treatment of adenovirus infections. Reviews in Medical Virology 18:6, 357-374
Online publication date: 1-Dec-2008.
CrossRef
Andrew P Rice, Richard E Sutton. (2007) Targeting protein–protein interactions for HIV therapeutics. Future HIV Therapy 1:4, 369-385
Online publication date: 1-Dec-2007.
CrossRef
 

Prev. Article | Next Article
View/Print PDF (151 KB)
View PDF Plus (225 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Author:
Nafsika Georgopapadakou
Keywords:
alovudine
anthrax vaccine
antivirals
aplaviroc
ciluprevir
Dermofural™
ISIS-14803
JTK-003
R803
topical econazole
Xcellerate™